



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Amifostine trihydrate (Standard)

Cat. No.:	HY-B0639AR
CAS No.:	112901-68-5
Molecular Formula:	C ₅ H ₂₁ N ₂ O ₆ PS
Molecular Weight:	268.27
Target:	MDM-2/p53; HIF/HIF Prolyl-Hydroxylase
Pathway:	Apoptosis; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Amifostine (trihydrate) (Standard) is the analytical standard of Amifostine (trihydrate). This product is intended for research and analytical applications. Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor- α 1 (HIF- α 1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action^{[1][2][3][4]}.

REFERENCES

- [1]. D Maurici, et al. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. *Oncogene*. 2001 Jun 14;20(27):3533-40.
- [2]. Efstathia Giannopoulou, et al. Amifostine inhibits angiogenesis in vivo. *J Pharmacol Exp Ther*. 2003 Feb;304(2):729-37.
- [3]. Michael I Koukourakis, et al. Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1 alpha. *Cancer Chemother Pharmacol*. 2004 Jan;53(1):8-14.
- [4]. John R Kouvaris, et al. Amifostine: the first selective-target and broad-spectrum radioprotector. *Oncologist*. 2007 Jun;12(6):738-47.
- [5]. Shao-Ze Wu, et al. Amifostine Pretreatment Attenuates Myocardial Ischemia/Reperfusion Injury by Inhibiting Apoptosis and Oxidative Stress. *Oxid Med Cell Longev*. 2017;2017:4130824.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA